<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05098470</url>
  </required_header>
  <id_info>
    <org_study_id>DK029953</org_study_id>
    <nct_id>NCT05098470</nct_id>
  </id_info>
  <brief_title>Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity</brief_title>
  <official_title>Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity on Endogenous Glucose Production in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has been shown that individuals with type 2 diabetes have higher blood sugar throughout&#xD;
      the night than individuals without type 2 diabetes. However, it is still unknown if this rise&#xD;
      in blood sugar can be controlled using medications.&#xD;
&#xD;
      This study will examine the effects of three different diabetes treatments to determine if&#xD;
      they improve night time blood sugars. Participants will be randomly assigned for 8 weeks to&#xD;
      one of the following three groups:&#xD;
&#xD;
      GROUP 1: Insulin. Participants will be instructed on self-injecting insulin glargine&#xD;
      once-daily in the morning. The dose will be increased by the study team to avoid episodes of&#xD;
      low blood sugar and to maintain fasting blood sugar concentrations between 70 to 180 mg/dl.&#xD;
&#xD;
      GROUP 2: Metformin. Participants will start the drug (500 mg twice daily) with meals. After&#xD;
      72 hours and in the absence of side effects, they will increase the dose to 500 mg with&#xD;
      breakfast and 1,000 mg with supper. After a further 72 hours and in the absence of side&#xD;
      effects, they will increase the dose to 1,000 mg twice daily with meals and continue until&#xD;
      the end of the trial. The dose will be adjusted by the study team to maintain fasting blood&#xD;
      sugar concentrations between 70 to 180 mg/dl.&#xD;
&#xD;
      GROUP 3: Dorzagliatin. This medication dose will be 75 mg twice daily. The investigators&#xD;
      anticipate fasting glucose concentrations will be between 70 to 180 mg/dl since the dose of&#xD;
      this medication cannot be titrated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contribution of gluconeogenesis (GNG) to endogenous glucose production (EGP)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Ratio of GNG to total EGP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Contribution of glycogenolysis (GLY) to EGP</measure>
    <time_frame>8 weeks</time_frame>
    <description>Ratio of GLY to total EGP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucokinase activity</measure>
    <time_frame>8 weeks</time_frame>
    <description>UDP glucose flux</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Glargine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dorzagliatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>1500-2000 mg per day for 8 weeks</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>Long-acting insulin for 8 weeks</description>
    <arm_group_label>Insulin Glargine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dorzagliatin</intervention_name>
    <description>Oral Glucokinase Activator 75 mg twice daily for 8 weeks</description>
    <arm_group_label>Dorzagliatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI:25-40 kg/m2.&#xD;
&#xD;
          -  HbA1C â‰¤ 9% on lifestyle therapy with or without monotherapy with metformin or&#xD;
             sulphonylureas (SU); or combination therapies (metformin and SU, DPPIV inhibitors,&#xD;
             only short acting GLP-1 analogues exenatide (Byeta) and liraglutide (Victoza).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Insulin therapy&#xD;
&#xD;
          -  SGLT2 inhibitors&#xD;
&#xD;
          -  Long acting GLP-1 analogues&#xD;
&#xD;
          -  TZDs&#xD;
&#xD;
          -  Medications affecting GI motility (e.g., erythromycin, pramlintide).&#xD;
&#xD;
          -  Medications that may affect glucose metabolism such as corticosteroids,&#xD;
             tricyclic-antidepressants, benzodiazepines, opiates, barbiturates, and anticoagulants.&#xD;
&#xD;
          -  Unstable diabetic retinopathy, microalbuminuria, macrovascular disease.&#xD;
&#xD;
          -  Upper GI disorder/surgery, debilitating chronic disease, anemia, and symptoms of&#xD;
             undiagnosed illnesses.&#xD;
&#xD;
          -  History of alcoholism or substance abuse.&#xD;
&#xD;
          -  Pregnancy or breast feeding, or other comorbidities precluding participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Supraja Gururaj, MD, MPH</last_name>
    <phone>434-924-3512</phone>
    <email>sg2ug@hscmail.mcc.virginia.edu</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 8, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Rita Basu, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

